

FORM 7

LEVITEE LABS INC.

**MONTHLY PROGRESS REPORT**

Name of CSE Issuer: Levitee Labs Inc. (the "Issuer").

Trading Symbol: LVT

Number of Outstanding Listed Securities: 83,543,440

Date: August 27, 2021

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**July 19, 2021**

**The Issuer has received final approval from the Canadian Securities Exchange ("CSE") to list its common shares on the CSE. At the opening of the market on July 21, the common shares of Levitee will begin trading under the ticker symbol "LVT".**

**July 23, 2021**

**The Issuer has signed definitive agreements to acquire clinics, pharmacies, and a telemedicine company in Alberta.**

2. Provide a general overview and discussion of the activities of management.

**See Item 1.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**July 28, 2021**

**The Issuer has completed the acquisition of all the issued and outstanding shares of telemedicine company BlockMD Ltd. as of July 27, 2021.**

**July 29, 2021**

**The Issuer has completed the acquisition of the majority of the operating assets of ACT Medical Centres Inc. as of July 28, 2021. These assets include 5 addiction treatment clinics across the province of Alberta that have conducted over 35,000 patient visits during the past 12 months. In consideration for the acquisition, Levitee paid \$350,000 in cash on the closing date.**

**The Issuer completed the acquisition of all the issued and outstanding shares of 2143327 Alberta Ltd., 2144209 Alberta Ltd., and 2017162 Alberta Ltd. for \$3,637,528 in cash.**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not applicable.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not applicable.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not applicable.**

14. Provide details of any securities issued and options or warrants granted.

**Not applicable.**

15. Provide details of any loans to or by Related Persons.

**Not applicable.**

16. Provide details of any changes in directors, officers or committee members.

**Not applicable.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Not applicable.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 27, 2021.

Mason Darabi  
*Name of Director or Senior Officer*

/s/Mason Darabi  
*Signature*

Chief Financial Officer  
*Official Capacity*

<b>Issuer Details</b> <i>Name of Issuer</i> <b>Levitee Labs Inc.</b>	<i>For Month End</i> <b>July, 2021</b>	<i>Date of Report</i> <i>YY/MM/DD</i> <b>21/08/27</b>
<i>Issuer Address</i> <b>#215 - 800 W. Pender Street</b>		
<i>City/Province/Postal Code</i> <b>Vancouver, BC V6C 1J8</b>	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> <b>(250) 465-8640</b>
<i>Contact Name</i> <b>Mackenzie Osborne</b>	<i>Contact Position</i> <b>Director</b>	<i>Contact Telephone No.</i> <b>(250) 465-8640</b>
<i>Contact Email Address</i> <b>ken@leviteelabs.com</b>	<i>Web Site Address</i>	